We are live on ! Find out more
ATNM icon

Actinium Pharmaceuticals
ATNM

54 hedge funds and large institutions have $5.27M invested in Actinium Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.35% less ownership

Funds ownership: 17.34% → 16.99% (-0.35%)

10% less funds holding

Funds holding: 60 → 54 (-6)

14% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 14

28% less capital invested

Capital invested by funds: $7.36M → $5.27M (-$2.08M)

42% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 12

Holders
54
Holders Change
-6
Holders Change %
-10%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
12
Reduced
14
Closed
12
Calls
$147K
Puts
–
Net Calls
+$147K
Net Calls Change
-$72K

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$152K
2
Renaissance Technologies
Renaissance Technologies
New York
+$96.1K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$49.4K
4
Northern Trust
Northern Trust
Illinois
+$39.5K
5
TSS
Two Sigma Securities
New York
+$27.3K

Top Sellers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
-$89.4K
2
B
Bailard
California
-$78.7K
3
Jane Street
Jane Street
New York
-$70K
4
Millennium Management
Millennium Management
New York
-$44K
5
Cetera Investment Advisers
Cetera Investment Advisers
Illinois
-$20.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northwestern Mutual Wealth Management
51
Northwestern Mutual Wealth Management
Wisconsin
$106 – – –
Fidelity Investments
52
Fidelity Investments
Massachusetts
$79 -$17K -14,294 -99%
CIAM
53
Caitong International Asset Management
Hong Kong
$1 +$1 +1 New
Two Sigma Advisers
54
Two Sigma Advisers
New York
– -$267K -196,076 Closed
Squarepoint
55
Squarepoint
New York
– -$89.4K -65,730 Closed
B
56
Bailard
California
– -$78.7K -57,867 Closed
Cetera Investment Advisers
57
Cetera Investment Advisers
Illinois
– -$20.8K -15,259 Closed
Russell Investments Group
58
Russell Investments Group
United Kingdom
– -$18.1K -13,340 Closed
HF
59
HRT Financial
New York
– -$17K -13,010 Closed
Point72 Asset Management
60
Point72 Asset Management
Connecticut
– -$14K -10,295 Closed
AAP
61
Arax Advisory Partners
Colorado
– -$962 -707 Closed
Bank of America
62
Bank of America
North Carolina
– -$882 -649 Closed
Royal Bank of Canada
63
Royal Bank of Canada
Ontario, Canada
– -$42 -35 -44%
EWA
64
EverSource Wealth Advisors
Alabama
– -$22 -16 Closed
EP
65
Essential Partners
California
– -$5 -4 Closed
Barclays
66
Barclays
United Kingdom
– -$1 -1 Closed
1 2
3

ATNM Hedge Fund Activity: Q1 2026 in Review

54 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q1 2026, worth a combined $5.27M — down 28% from $7.36M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ATNM and 7 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 12 added.

The largest buyer was Two Sigma Investments, adding an estimated $152K. The largest seller was Squarepoint, exiting entirely with an estimated $89.4K sold.

  • 54 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q1 2026, down from 60 in Q4 2025.
  • Funds reported $5.27M of Actinium Pharmaceuticals stock for Q1 2026, down 28% quarter-over-quarter.
  • 7 funds opened new Actinium Pharmaceuticals positions in Q1 2026 and 12 closed out, a net change of -5 holders.
  • The largest Actinium Pharmaceuticals buyer in Q1 2026 was Two Sigma Investments, an estimated $152K added.
  • The largest Actinium Pharmaceuticals seller in Q1 2026 was Squarepoint, an estimated $89.4K sold.

Based on aggregated 13F filings for Q1 2026.